SCHEMBL23014686

SCHEMBL23014686

COC(=O)c1ccccc1NS(=O)(=O)C1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.57
ALDH1A1 P00352 5/20 0.57
HSD17B10 Q99714 2/20 0.57
HPGD P15428 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
TSHR P16473 2/20 0.56
MRGPRX1 Q96LB2 5/20 0.55
RECQL P46063 1/20 0.52
POLB P06746 2/20 0.52
GAA P10253 1/20 0.52
ALOX12 P18054 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM1A O60341 1/20 0.52
ATM Q13315 1/20 0.50
MAPK10 P53779 1/20 0.48
ACLY P53396 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23014676 0.84 ACLY (0.65) KDM4EALDH1A1HSD17B10HPGDMRGPRX1
SCHEMBL647703 0.79 TSHR (0.82) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL7065164 0.77 KDM4E (0.70) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL18594835 0.77 KDM4E (0.70) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL19335455 0.77 KDM4E (0.70) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL31393942 0.76 ACLY (0.62) KDM4EALDH1A1HSD17B10HPGDMRGPRX1
SCHEMBL1015878 0.75 CA1 (0.58) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL27592220 0.75 TSHR (0.47) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL21384614 0.75 MRGPRX1 (0.57) MRGPRX1ACLY
SCHEMBL22638690 0.75 MRGPRX1 (0.54) KDM4EALDH1A1HSD17B10HPGDMRGPRX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-02-03 US disclosed
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-10-06 US disclosed
WO-2021035031-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315528-A1 INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE LCAT, AGPAT2, AGPAT5 KDM4E 3007/4885ALDH1A1 2938/4885HSD17B10 372/4885
US-12540115-B2 Inhibitors of phospholipid synthesis and methods of use LCAT, DGAT1, DGAT2 KDM4E 1824/4885ALDH1A1 1934/4885HSD17B10 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.